Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.56 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503423 | 0.91 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL17198376 | 0.90 | LMNA (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL18503443 | 0.90 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL17198352 | 0.88 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL2056615 | 0.88 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL2921711 | 0.88 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL6545745 | 0.88 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL25924676 | 0.88 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL6226229 | 0.88 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL26644222 | 0.88 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | SLC28A1 82/4885SLC28A2 32/4885SLC29A1 165/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | SLC28A1 79/4885SLC28A2 31/4885SLC29A1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.